Sanofi (SNYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanofi (SNYN) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$1.68 Billion ≈ $96.86 Million USD) by net assets (MX$73.14 Billion ≈ $4.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sanofi liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Sanofi - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Sanofi's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sanofi Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marriott International Inc
NASDAQ:MAR
|
-0.210x |
|
Sanofi
F:SNW2
|
0.051x |
|
Medtronic plc
SA:MDTC34
|
0.097x |
|
Mizuho Financial Group Inc.
NYSE:MFG
|
-0.200x |
|
GlaxoSmithKline plc
MX:GSKN
|
0.141x |
|
AIR LIQUIDE ADR 1/5/EO 11
F:AILA
|
N/A |
|
INTESA SANPAOLO ADR/6
F:IESJ
|
N/A |
|
State Bank of India
NSE:SBIN
|
-0.265x |
Annual Cash Flow Conversion Efficiency for Sanofi (2013–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Sanofi (SNYN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$71.71 Billion ≈ $4.13 Billion |
MX$10.75 Billion ≈ $618.67 Million |
0.150x | +28.53% |
| 2024-12-31 | MX$77.86 Billion ≈ $4.48 Billion |
MX$9.08 Billion ≈ $522.61 Million |
0.117x | -15.46% |
| 2023-12-31 | MX$74.35 Billion ≈ $4.28 Billion |
MX$10.26 Billion ≈ $590.35 Million |
0.138x | -3.65% |
| 2022-12-31 | MX$73.51 Billion ≈ $4.23 Billion |
MX$10.53 Billion ≈ $605.77 Million |
0.143x | -6.06% |
| 2021-12-31 | MX$69.03 Billion ≈ $3.97 Billion |
MX$10.52 Billion ≈ $605.54 Million |
0.152x | +29.75% |
| 2020-12-31 | MX$63.15 Billion ≈ $3.63 Billion |
MX$7.42 Billion ≈ $426.91 Million |
0.117x | -10.00% |
| 2019-12-31 | MX$59.11 Billion ≈ $3.40 Billion |
MX$7.71 Billion ≈ $444.00 Million |
0.131x | +38.91% |
| 2018-12-31 | MX$59.03 Billion ≈ $3.40 Billion |
MX$5.55 Billion ≈ $319.23 Million |
0.094x | -25.82% |
| 2017-12-31 | MX$58.26 Billion ≈ $3.35 Billion |
MX$7.38 Billion ≈ $424.66 Million |
0.127x | -6.72% |
| 2016-12-31 | MX$57.72 Billion ≈ $3.32 Billion |
MX$7.84 Billion ≈ $451.08 Million |
0.136x | -11.39% |
| 2015-12-31 | MX$58.21 Billion ≈ $3.35 Billion |
MX$8.92 Billion ≈ $513.35 Million |
0.153x | +12.12% |
| 2014-12-31 | MX$56.27 Billion ≈ $3.24 Billion |
MX$7.69 Billion ≈ $442.56 Million |
0.137x | +12.09% |
| 2013-12-31 | MX$57.03 Billion ≈ $3.28 Billion |
MX$6.95 Billion ≈ $400.20 Million |
0.122x | -- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more